GH Stock Forecast & Price Target

Guardant Health is well positioned fundamentally because it combines clear market leadership in liquid biopsy with multiple revenue engines—Guardant360 for tumor profiling, Reveal for MRD, and Shield for colorectal screening—that are each gaining clinical validation, payer support, and broader commercial adoption. Recent catalysts materially strengthen the investment case: Q1’26 revenue of $302M grew 48% year over year, oncology test volumes rose 47%, Shield revenue was about $42M on roughly 44k tests, and the company raised its 2026 revenue guide to $1.30B-$1.32B while retaining 64%-65% gross margin guidance. The outlook is further supported by expanding reimbursement and pricing power, including UNH coverage for Shield effective August 1, 2026, ACS and NCCN guideline inclusion, FDA approval of Guardant360 CDx that supports a higher $8,455 list price and potential ADLT-driven ASP expansion, plus a strong cash position of $1.2B and a path to operating leverage as screening and monitoring penetration scale.

Guardant Health is a market leader in liquid biopsy, but its fundamentals are challenged by a commercial model that still depends on uncertain adoption across multiple emerging markets, while competition in precision oncology, tissue testing, MRD, and early detection limits pricing power and share gains. The screening opportunity is especially vulnerable because the market for blood-based cancer screening is smaller than expected, the ultimate addressable size remains debated due to performance trade-offs and uncertain multi-cancer accuracy, and broad reimbursement still hinges on external guideline and policy decisions that are inherently unpredictable. Although the company has meaningful product breadth and catalyst potential, the fact that it has burned more than $200M in cash in each of the past two years, with burn accelerating year-over-year in the most recent quarter, underscores execution risk and balance-sheet pressure if management’s breakeven target by Q4 2027 slips.